Cichoric acid, a phenolic compound primarily found in Echinacea species and chicory, has been the subject of limited scientific investigation regarding its role in supporting or treating Inflammatory Bowel Disorders (IBD) such as Crohn’s disease and ulcerative colitis. Preclinical studies, mostly in animal models, suggest that cichoric acid possesses anti-inflammatory and antioxidant properties. For example, research in mouse models of colitis has shown that cichoric acid administration can reduce disease severity, decrease pro-inflammatory cytokine levels (such as TNF-α and IL-6), and ameliorate oxidative stress in intestinal tissues. Mechanistically, cichoric acid appears to modulate pathways like NF-κB, which is implicated in inflammatory responses in IBD. However, these effects have not yet been validated in well-controlled human clinical trials, and data in humans are lacking. While traditional use of Echinacea (which contains cichoric acid) is more often associated with immune support and not specifically with IBD, the emerging scientific evidence from animal and in vitro studies provides a rationale for further investigation. Overall, the use of cichoric acid for IBD is supported by early-stage scientific evidence, but clinical efficacy and safety in humans remain uncertain.